Related Experiment Video
Updated: Jul 14, 2026
Reverse Genetics Mediated Recovery of Infectious Murine Norovirus
Published on: June 24, 2012
A nucleoside-modified mRNA vaccine prevents enterovirus A71 infection in mouse model
Fengyu Chi1,2, Xu Zhang1,2, Dong Zhang1,2
1School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, China.
Introduction:
Human Enterovirus A71 (EV-A71) is the primary pathogen responsible for severe hand, foot, and mouth disease (HFMD). Vaccination plays a crucial role in controlling its spread. Although inactivated vaccines have been approved, there is growing interest in developing new candidates using advanced platforms. mRNA vaccines, widely used for enveloped viruses, are less studied for non-enveloped viruses like EV-A71. This study investigates the potential of an mRNA vaccine targeting the EV-A71 VP1 protein.
Methods:
A nucleoside-modified mRNA vaccine encoding the VP1 protein of EV-A71, encapsulated in lipid nanoparticles (LNPs), was developed. Immunogenicity and protective efficacy were evaluated in BALB/c and neonatal A129 mice, respectively. Immune responses were assessed by ELISA, micro-neutralization assays, ELISpot, and intracellular cytokine staining (ICS). Passive protection was tested by transferring immune sera to neonatal mice challenged with EV-A71.
Results:
The VP1 mRNA-LNP vaccine elicited robust humoral and cellular immunity, including high levels of VP1-specific IgG, neutralizing antibodies, and a Th1-biased T-cell response. Notably, the mRNA vaccine outperformed the inactivated vaccine in eliciting cellular immunity. Immune sera provided complete protection against lethal EV-A71 challenge, significantly reducing viral load and pathology.
Discussion:
This study demonstrates that the mRNA vaccine exhibits significant potential for combating non-enveloped viruses. These findings highlight the promising role of mRNA platforms in advancing vaccine development against non-enveloped viral pathogens, offering new avenues for future research and clinical applications.
Insights
A novel mRNA vaccine targeting the Enterovirus A71 (EV-A71) VP1 protein shows promise for hand, foot, and mouth disease (HFMD) control. This EV-A71 mRNA vaccine effectively elicits protective immunity, offering a new strategy against non-enveloped viruses.
Area of Science:
- Virology
- Vaccinology
- Immunology
Background:
- Human Enterovirus A71 (EV-A71) is the main cause of severe hand, foot, and mouth disease (HFMD).
- Current inactivated vaccines exist, but advanced platforms like mRNA vaccines are being explored for non-enveloped viruses such as EV-A71.
Purpose of the Study:
- To investigate the immunogenicity and protective efficacy of a nucleoside-modified mRNA vaccine encoding the EV-A71 VP1 protein.
Main Methods:
- Developed an mRNA vaccine encoding EV-A71 VP1 protein encapsulated in lipid nanoparticles (LNPs).
- Evaluated immunogenicity and protective efficacy in mouse models (BALB/c and neonatal A129).
- Assessed immune responses using ELISA, micro-neutralization assays, ELISpot, and intracellular cytokine staining (ICS).
Main Results:
- The mRNA-LNP vaccine induced strong humoral and cellular immunity, including high levels of VP1-specific IgG and neutralizing antibodies.
- A Th1-biased T-cell response was observed, with the mRNA vaccine outperforming an inactivated vaccine in cellular immunity.
- Immune sera conferred complete protection against lethal EV-A71 challenge, reducing viral load and pathology.
Conclusions:
- The developed mRNA vaccine shows significant potential for combating non-enveloped viruses like EV-A71.
- mRNA vaccine platforms offer a promising new avenue for developing vaccines against non-enveloped viral pathogens.
